The Pharmacopoeial Discussion Group (PDG) announced the Indian Pharmacopoeia Commission (IPC) as a PDG member on October 5, 2023.
- IPC officially joined as a member in the PDG at the PDG’s Annual Meeting which was held on October 3-4, 2023 in Hyderabad.
- The World Health Organization (WHO) also continues to serve as observer of the PDG.
- The PDG, will now bring together the European Pharmacopoeia (Ph. Eur.), the Japanese Pharmacopoeia (JP), the United States Pharmacopeia (USP) and Indian Pharmacopoeia (IP) to harmonize global pharmacopoeial standards.
- The objective is to reduce manufacturers’ burden of having to perform analytical procedures in different ways, using different acceptance criteria, in order to satisfy pharmacopoeial requirements that vary across regions.
- Inclusion of IP in PDG will significantly increase the visibility of the Indian Pharmacopoia on international platform.
- IPC’s inclusion in PDG will help in effort towards its recognition by other countries.
- It will help IPC to collaborate and harmonize pharmacopoeial standards with other major regulatory/standard setting authorities which in turn will help in ensuring the quality and safety of pharmaceuticals at a global level.
- A pharmacopoeial general chapter or other pharmacopoeial document is harmonized when a pharmaceutical substance or product tested by the document’s harmonized procedure yields the same results and the same accept/reject decision is reached.
